CureVac NV
NASDAQ:CVAC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.31
6.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
CureVac NV
CureVac NV
Net Income (Common)
CureVac NV
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CureVac NV
NASDAQ:CVAC
|
Net Income (Common)
-€260.2m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Net Income (Common)
€930.3m
|
CAGR 3-Years
296%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Net Income (Common)
-€460.3m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Net Income (Common)
-€97m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Net Income (Common)
€68.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
10%
|
|
|
Formycon AG
XETRA:FYB
|
Net Income (Common)
€75.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
CureVac NV
Glance View
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
See Also
What is CureVac NV's Net Income (Common)?
Net Income (Common)
-260.2m
EUR
Based on the financial report for Dec 31, 2023, CureVac NV's Net Income (Common) amounts to -260.2m EUR.
What is CureVac NV's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-30%
Over the last year, the Net Income (Common) growth was -4%. The average annual Net Income (Common) growth rates for CureVac NV have been -26% over the past three years , -30% over the past five years .
You don't have any saved screeners yet
